Cancer of the ProstatePhase 2NCT00744549
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
A Phase 2 study testing Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E in people with Cancer of the Prostate and Prostate Cancer, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
The purpose of this study is to determine whether antioxidants (vitamin E, selenium and lycopene)can change(reduce)prostate tumor size or blood flow to the prostate as determined by MRI imaging among men on Active Surveillance. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Cancer of the Prostate, Prostate Cancer, Prostatic Neoplasms
- What is being tested?
- Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteCanada
- Study dates
- May 2008to Dec 2013
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- MRI detectable prostate cancer
- PSA less than 15 ng/ml
- Gleason score <= 7
- Prostate cancer staging T1c or T2a
Who cannot join
- Concurrent use of high-dose vitamins which include selenium, lycopene, vitamin D or vitamin E
- Other malignancies diagnosed or requiring treatment within the past 5 years (except superficial bladder cancer or basal cell carcinoma)
- Current use of Proscar or Avodart
Trial locations and contacts
1 site in 1 country.
Canada1 site
University Health Network - Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
About this study
Official title: The Impact of Antioxidants on MRI Markers of Cell Proliferation and Hypoxia Among Men on Active Surveillance With Early Stage Prostate Cancer
The purpose of this study is to determine whether antioxidants (vitamin E, selenium and lycopene)can change(reduce)prostate tumor size or blood flow to the prostate as determined by MRI imaging among men on Active Surveillance.
- Conditions
- Cancer of the Prostate, Prostate Cancer, Prostatic Neoplasms
- Being tested
- Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E, Placebo
- Keywords
- Male Urogenital Diseases, Antioxidants, Vitamin E, Vitamin D, Lycopene, Selenium
- Medical subject headings
- Prostatic Neoplasms, Male Urogenital Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin EDietary supplement
Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
PlaceboDrug
Twice a day with meals.
| Study group | Role | What they receive |
|---|---|---|
| A | Experimental | This group of men will be on active treatment (antioxidants) for one year and placebo for the second year. Receives: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo |
| B | Experimental | This group of men will be on placebo for one year and active treatment (antioxidants) for the second year. Receives: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine the impact of combination vitamin E, lycopene, and selenium on MRI detected prostate tumor size and/or tumor blood flow among me on active surveillance
Measured: At baseline MRI compared to 1-year MRI compared to 2-year MRI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2008 (estimated)
- Study startMay 2008
- Primary completionDec 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer of the ProstateStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- The Prostate Cancer Research Foundation of Canada
- Responsible party
- Sponsor
- Investigators
- Neil Fleshner, Principal investigator, Princess Margaret Hospital, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00744549
- Sponsor's protocol ID
- 07-0580-B
- Status last verified
- Feb 2018
- First submitted
- 29 Aug 2008
- Last updated
- 14 Feb 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Antioxidants on MRI Markers of Cell Proliferation and Hypoxia Among Men on Active Surveillance With Early Stage Prostate Cancer
- ClinicalTrials.gov ID
- NCT00744549
- Acronym / sponsor ID
- 07-0580-B
- Conditions
- Cancer of the Prostate, Prostate Cancer, Prostatic Neoplasms
- Keywords
- Male Urogenital Diseases, Antioxidants, Vitamin E, Vitamin D, Lycopene, Selenium
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Collaborators
- The Prostate Cancer Research Foundation of Canada
- Study start
- May 2008
- Primary completion
- Dec 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 1 Sep 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether antioxidants (vitamin E, selenium and lycopene)can change(reduce)prostate tumor size or blood flow to the prostate as determined by MRI imaging among men on Active Surveillance.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A | Experimental | Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E, Drug: PlaceboThis group of men will be on active treatment (antioxidants) for one year and placebo for the second year. |
| B | Experimental | Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E, Drug: PlaceboThis group of men will be on placebo for one year and active treatment (antioxidants) for the second year. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- MRI detectable prostate cancer
- PSA less than 15 ng/ml
- Gleason score <= 7
- Prostate cancer staging T1c or T2a
Key exclusion criteria (3 listed)
- Concurrent use of high-dose vitamins which include selenium, lycopene, vitamin D or vitamin E
- Other malignancies diagnosed or requiring treatment within the past 5 years (except superficial bladder cancer or basal cell carcinoma)
- Current use of Proscar or Avodart
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin ETwice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU | Dietary supplement | A, B |
| PlaceboTwice a day with meals. | Drug | A, B |
Primary outcome
To determine the impact of combination vitamin E, lycopene, and selenium on MRI detected prostate tumor size and/or tumor blood flow among me on active surveillance
Time frame: At baseline MRI compared to 1-year MRI compared to 2-year MRI
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2018.
Related trials for Cancer of the Prostate
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Neil Fleshner principal investigator
Princess Margaret Hospital, Canada
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E in people with Cancer of the Prostate and Prostate Cancer, run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine the impact of combination vitamin E, lycopene, and selenium on MRI detected prostate tumor size and/or tumor blood flow among me on active surveillance (time frame: At baseline MRI compared to 1-year MRI compared to 2-year MRI). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2018.